Systems biology approaches toward autosomal dominant polycystic kidney disease (ADPKD)

Abstract

BackgroundAutosomal dominant polycystic kidney disease (ADPKD), a common of monogenetic disorder caused by the polycystic kidney disease‐1 (PKD1) or PKD2 genes deficiency. In this study, we have re‐analyzed a microarray dataset to generate a holistic view of this disease. MethodologyGSE7869, an expression profiling dataset was downloaded from the Gene Expression Omnibus (GEO) database. After quality control assessment, using GEO2R tool of GEO, genes with adjusted p‐value ≤ 0.05 were determined as differentially expressed (DE). The expression profiles from ADPKD samples in different sizes were compared. Using CluePedia plugin of Cytoscape software, the protein–protein interaction (PPI) networks were constructed and analyzed by Cytoscape NetworkAnalyzer tool and MCODE application. Pathway enrichment analysis of clustered genes by MCODE with the high centrality parameters in PPI networks was performed using Cytoscape ClueGO plugin. Moreover, by Enrichr database, microRNAs (miRNAs) and transcription factors (TFs) targeted DE genes were identified. ResultsIn this study to explore the molecular pathogenesis of kidney in ADPKD, mRNA expression profiles of cysts from patients in different sizes were re‐analyzed. The comparisons were performed between normal with minimally cystic tissue (MCT) samples, MCTs with small cysts, and small cysts with large cysts. 512, 7024, and 655 DE genes were determined, respectively. The top central genes, e.g. END1, EGFR, and FOXO1 were identified with topology and clustering analysis. DE genes that were significantly enriched in PPI networks are critical genes and their roles in ADPKD remain to be assessed in future experimental studies beside miRNAs and TFs predicted. Furthermore, the functional analysis resulted in which most of them are expected to be associated with ADPKD pathogenesis, such as signal pathways that involved in cell growth, inflammation, and cell polarity. ConclusionWe have here explored systematic approaches for molecular mechanisms assay of ADPKD as a monogenic disease, which may also be used for other monogenetic diseases beside complex diseases to provide suitable therapeutic targets.

Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study.

“…We also found that the Kyn:Trp ratio increased to a greater extent in SARS-CoV2 patients with severe lymphopenia. Lymphopenia is a specific hallmark of severe SARS-CoV2 infection with respect to other viral infections, and occurs as a result of multiple mechanisms, including infiltration and trapping of T lymphocytes in the lower respiratory tract, poly-ADP ribose polymerase (PARP) activation and NAD + depletion in immune cells, or expression of protein 7a [ 20 ]. In SARS-CoV2 patients, the kynurenine pathway might be induced in antigen-presenting cells and mucosal epithelial cells of the respiratory tract in response to proinflammatory cytokines produced by resident cells of the innate immunity or by infiltrating T lymphocytes [ 21 ].…”

Granulocytes and Cells of Granulocyte Origin—The Relevant Players in Colorectal Cancer

“…These observations led to the conclusion that the blood basophil count might be associated with the prognosis in CRC. There are only a few articles on this topic, suggesting that a low blood level of basophils before treatment is associated with worse prognosis and higher tumor aggressiveness [ 31 , 32 , 37 ]. For example, in patients with resectable CRC, pretreatment basophilia correlated with better prognosis during a 5-year observation period (better OS and DFS) [ 32 ].…”

Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters

“…It is originally present in bacteria and archaea as an “immune system” to protect these organisms against phage and other viral infections. One interesting feature of CRISPR systems is that they use a guide RNA (gRNA) that binds to the DNA target site while a nuclease known as CRISPR-associated caspase protein (Cas) cleaves specific DNA strands which are complementary to the RNAg of the CRISPR system ( 53 ). This gene editing system can be used for raising adaptive immunity, fighting carcinomas and specific mutation editing ( 54 ).…”